Mark J. Pykett

2012

In 2012, Mark J. Pykett earned a total compensation of $1.9M as Chief Executive Officer at Navidea Biopharmaceuticals, a 161% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$140,250
Option Awards$385,462
Salary$425,000
Stock Awards$983,700
Other$13,808
Total$1,948,220

Pykett received $983.7K in stock awards, accounting for 50% of the total pay in 2012.

Pykett also received $140.3K in non-equity incentive plan, $385.5K in option awards, $425K in salary and $13.8K in other compensation.

Rankings

In 2012, Mark J. Pykett's compensation ranked 3,651st out of 11,487 executives tracked by ExecPay. In other words, Pykett earned more than 68.2% of executives.

ClassificationRankingPercentile
All
3,651
out of 11,487
68th
Division
Manufacturing
1,253
out of 4,253
71st
Major group
Chemicals And Allied Products
282
out of 1,198
77th
Industry group
Drugs
164
out of 920
82nd
Industry
In Vitro and In Vivo Diagnostic Substances
6
out of 47
87th
Source: SEC filing on June 5, 2015.

Pykett's colleagues

We found four more compensation records of executives who worked with Mark J. Pykett at Navidea Biopharmaceuticals in 2012.

2012

Thomas Tulip

Navidea Biopharmaceuticals

President and Chief Business Officer

2012

Frederick Cope

Navidea Biopharmaceuticals

Chief Scientific Officer

2012

Brent Larson

Navidea Biopharmaceuticals

Chief Financial Officer

2012

Rodger Brown

Navidea Biopharmaceuticals

Vice President, Global Regulatory Operations and Quality Assurance

You may also like